A5101530475- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Cancer-related Molecular Pathways
- Lung Cancer Research Studies
- Chronic Lymphocytic Leukemia Research
- Functional Brain Connectivity Studies
- Neuroscience and Neuropharmacology Research
- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- Neurotransmitter Receptor Influence on Behavior
- Glioma Diagnosis and Treatment
- Microtubule and mitosis dynamics
- Neuroendocrine Tumor Research Advances
- Tryptophan and brain disorders
- Treatment of Major Depression
- Radiomics and Machine Learning in Medical Imaging
- Mechanisms of cancer metastasis
- Hippo pathway signaling and YAP/TAZ
- Genetic Associations and Epidemiology
- Lymphoma Diagnosis and Treatment
- Cholesterol and Lipid Metabolism
- Immune cells in cancer
- Colorectal Cancer Treatments and Studies
- Phytoestrogen effects and research
- Urinary and Genital Oncology Studies
Aerospace Center Hospital
2024
Kunming Medical University
2023-2024
First Affiliated Hospital of Kunming Medical University
2023-2024
Zhejiang University
2024
Sir Run Run Shaw Hospital
2024
Tianjin Medical University General Hospital
2020-2024
Southern University of Science and Technology
2024
Eli Lilly (United States)
2018-2023
Shandong First Medical University
2022
Shandong Provincial Hospital
2022
Statistically significant overall survival (OS) benefits of CDK4 and CDK6 inhibitors in combination with fulvestrant for hormone receptor (HR)-positive, ERBB2 (formerly HER2)-negative advanced breast cancer (ABC) patients regardless menopausal status after prior endocrine therapy (ET) has not yet been demonstrated.To compare the effect abemaciclib plus vs placebo on OS at prespecified interim MONARCH 2 (338 events) HR-positive, ERBB2-negative that progressed during ET.MONARCH was a global,...
Aim: To compare the efficacy, safety, and tolerability of abemaciclib plus endocrine therapy (ET) versus ET alone in postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced breast cancer (ABC) from China, Brazil, India, South Africa. Methods: This randomized, double-blind, phase III study was conducted between 9 December 2016 29 March 2019. Postmenopausal HR-positive, HER2-negative ABC no prior systemic an setting (cohort A) or...
Stromal fibroblasts are suggested to be a key determinant in the malignant progression of breast cancer. To find an vitro culture model that best mimics vivo tumor microenvironment so we can study effects stromal on cancer progression, evaluated several three-dimensional (3D) co-culture models order identify most suitable for our study. The purpose is co-culturing mouse 4T1 cells and murine embryonic (MEF) form spheroids with matrigel. We found forming aggregates/spheroids was, absence...
1059 Background: Abemaciclib is a selective inhibitor of CDK4 & 6 approved to treat HR+, HER2- metastatic breast cancer (MBC) patients (pts) as monotherapy and in combination with fulvestrant. In preclinical models, abemaciclib administered anti-programmed death-ligand 1 (PD-L1) antibody therapy synergistically induced anti-tumor response immunologic memory. A Phase I study (JPBJ, NCT02079636) plus pembrolizumab (Merck Co.), programmed death receptor (PD-1) antibody, demonstrated stable...
Abstract Background In MONARCH 2, abemaciclib plus fulvestrant significantly improved median progression-free survival (PFS, 16.4 vs 9.3 months, hazard ratio [HR] 0.553) and overall (OS, 46.7 37.3 months; HR 0.757) compared with placebo in hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative) advanced breast cancer (ABC) patients who were endocrine therapy (ET) resistant, regardless of menopausal status. Here, we report findings the...
Ovarian cancer is a malignant tumor in women all over the world. Ropivacaine identified as potential drug for treatment of tumors, but role and mechanism ropivacaine ovarian remains unknown.Ovarian cells were treated with different doses ropivacaine. The function was assessed using Cell Counting Kit-8 assay, flow cytometry, sphere-formation Western blot, Fe2+ level analysis, immunofluorescence. Meanwhile, investigated by multiple molecular experiments. protective further confirmed vivo...
BackgroundIn recent years, the combination of targeted drugs, such as Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, with endocrine therapy (ET), has emerged a new research focus in treatment hormone receptor-positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer. This network meta-analysis aimed to systematically evaluate efficacy and safety CDK4/6 inhibitors combined ET for HR+/HER2- cancer.MethodsA systematic search was conducted across PubMed, Web...
Abstract Background Melancholic depression (MD) is one of the most prevalent and severe subtypes major depressive disorder (MDD). Previous studies have revealed inconsistent results regarding alterations in grey matter volume (GMV) hippocampus amygdala MD patients, possibly due to overlooking complexity their internal structure. The consist multiple functionally distinct subregions, these subregions may play different roles MD. This study aims investigate volumetric each subregion patients...
The aim of this study was to develop and validate a radiomics nomogram for preoperative prediction Ki-67 proliferative index (Ki-67 PI) expression in patients with meningioma.
Evidence from previous literature suggests that the nucleus accumbens (NAc), hippocampus, and amygdala play critical roles in reward circuit. Meanwhile, it was also suggested abnormalities circuit might be closely associated with symptom of anhedonia depression. However, few studies have investigated structural alterations NAc, depression as main clinical manifestation. Thus, current study aimed to explore changes subcortical regions among melancholic (MD) patients, especially amygdala,...
Cisplatin (DDP) is commonly used in the treatment of non-small cell lung cancer (NSCLC), including adenocarcinoma (LUAD), and primary cause for its clinical inefficacy chemoresistance. Here, we aimed to investigate a novel mechanism chemoresistance LUAD cells, focusing on calcium-sensing receptor (CaSR). In this study, high CaSR expression was detected DDP-resistant elevated strongly correlated with poor prognosis patients receiving chemotherapy. cells exhibited decreased sensitivity...
Abstract Background: Abemaciclib is a selective and potent small molecule inhibitor of CDK4 6, with evidence single-agent antitumor activity, safety profile that enables dosing on continuous schedule. demonstrated anti-tumor activity as single agent 19.7% objective response rate for women previously treated HR+, HER2- MBC1. In the phase 1b study JPBH, abemaciclib tolerable when combined endocrine or HER2 targeted agents MBC2. given BID in combination pembrolizumab also stage IV NSCLC3....
Background The risk of atrial fibrillation (AF) is increased in individuals with gastroesophageal reflux disease (GERD), according to observational research. causal significance this association still unclear. This study sought assess GERD's role as a potential contributing factor AF. Methods With the use two-sample Mendelian randomization (MR) technique, we assessed relationship between GERD and genetic variants was examined using data from recent genome-wide (GWAS) that included 602,604...
Our study aims to explore the differences in functional connectivity nucleus accumbens (NAc) between patients with melancholic depression and non-melancholic (NMD) their relation depression's pathogenesis. We recruited 60 depression, 58 NMD, 80 healthy controls, all matched for gender, age, education. Functional analysis focused on bilateral NAc as region of interest, comparing it whole brain correlating significant clinical scores. Melancholic showed reduced left anterior regions, right...
Abstract Purpose: In MONARCH 2, abemaciclib plus fulvestrant significantly prolonged progression-free survival (PFS) and overall (OS) versus placebo in patients with hormone receptor positive (HR+), HER2− advanced breast cancer. This exploratory analysis assessed the efficacy of across subgroups receiving study therapy as first- or second-line treatment for metastatic disease. Patients Methods: Improvements were estimated using Cox models, a test interactions was performed. Results: The...
9059 Background: Abemaciclib is a potent and selective inhibitor of CDK4 & 6 approved for treatment HR+, HER2- metastatic breast cancer. In Phase 1 study, abemaciclib showed activity in pts with advanced and/or NSCLC. This 2 study evaluated the safety efficacy vs docetaxel Stage IV sqNSCLC previously treated platinum-based chemotherapy. Methods: multicenter, randomized, open-label trial, (200 mg PO every 12 hours daily) (75 mg/m2 on Day 1); both 21 day cycle until disease progression. Adults...
TPS7583 Background: Covalent (c) Bruton tyrosine kinase inhibitors (BTKi) have reshaped the treatment landscape for chronic lymphocytic leukemia/small lymphoma (CLL/SLL) and are now often used as initial therapy. The MURANO study established 2-year fixed duration venetoclax plus rituximab a standard of care regimen patients with relapsed or refractory CLL/SLL. However, its efficacy has not been formally assessed in CLL/SLL treated cBTKi, common setting where this is contemporary practice....
Abstract Background: In MONARCH 2, abemaciclib plus fulvestrant significantly improved median progression-free survival (PFS, 16.4 vs 9.3 months, hazard ratio [HR], 0.553) and overall (OS, 46.7 37.3 months; HR, 0.757) compared with placebo in hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative) advanced breast cancer (ABC) patients who were endocrine therapy (ET) resistant, regardless of menopausal status. Here, we report findings the...
Objectives: Melancholic depression (MD) is a common subtype of major depressive disorder (MDD). It difficult to treat because its neurobiological basis poorly understood. Therefore, investigate whether MD patients have any structural changes in gray matter (GM) and the molecular foundation these changes, we combined voxel-based morphometry (VBM) analysis with neurotransmitter system-derived mapping from public data. Methods: 137 drug-naive MDD 75 healthy controls (HCs) were recruited for...
1061 Background: In MONARCH 2 (M2), abemaciclib (A), an oral selective cyclin dependent kinase 4 & 6 inhibitor, + fulvestrant (F) demonstrated statistically significant improvements in progression-free survival (PFS) and overall (OS) compared to placebo (P) F hormone receptor positive (HR+), human epidermal growth factor negative (HER2-) advanced breast cancer (ABC). Numerically more pronounced PFS OS improvement was noted subgroups (Sub) with visceral (V) disease primary endocrine...
Cyclin-Dependent kinases (CDKs) function in mitosis by allowing the cycle to progress from one stage another due their properties as a family of protein kinases. Because this function, abnormalities with CDKs can lead uncontrolled cell division, leading diseases such cancer. Breast cancer is form which are prevalent area study. The role play controlling and coordinating division makes it an important process understand breast and, specifically, metastasis Lack controlled CDK could allow...